INmune Bio announced that the FDA granted Fast Track designation to its drug XPro1595 for treating early Alzheimer's disease, including mild cognitive impairment and mild dementia stages. This designation aims to speed up the development and review process due to the drug's potential to address neuroinflammation, a key factor in Alzheimer's progression. XPro1595 selectively targets soluble TNF to reduce brain inflammation while preserving immune functions. The company plans a Phase 2b/3 trial focusing on patients with biomarkers of inflammation to support regulatory approval.
Netflix currently holds $27 billion in cash and resources earmarked for buying back its own stock, which represents roughly 8% of the company's total shares. This significant buyback capacity indicates Netflix's confidence in its valuation and a stra...
On September 18, 2026, US spot Bitcoin ETFs attracted $433 million in net inflows, while spot Ethereum ETFs gained $144 million, marking a rebound from previous mixed sessions. Fidelity led Bitcoin ETF inflows with $311 million, and BlackRock led Eth...
Bitcoin is moving away from a weakness zone and may enter a stronger bullish phase, according to CryptoQuant's analysis. Although the market has not yet experienced extreme speculative mania, Bitcoin's price rose 2.5% to $78,240.79, with indicators s...
XRP is approaching a significant technical breakout with a daily close above $1.55, completing an inverse head-and-shoulders pattern that signals a potential 35% rally toward $2. This pattern has been developing since summer, with strong buyer suppor...
Prologis, a leading global logistics REIT, shows strong revenue and core FFO growth supported by steady rental income and expanding data center segments. However, its current valuation at a premium 26x AFFO multiple and a modest 3.2% dividend yield l...
